Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Azalea Therapeutics

Request full access

In vivo genomic medicines engineering T cells

Berkeley, United StatesFounded 2023Biotech & Life Sciences

About Azalea Therapeutics

Azalea Therapeutics is a biotechnology company developing precision genomic medicines that engineer a patient's own T cells directly inside the body. The company's core technology is its Enveloped Delivery Vehicles (EDV) platform, which is designed to deliver CRISPR-Cas9 cargo to specific cells for site-specific genome editing. This in vivo approach avoids the need for external lab manipulation and complex manufacturing, aiming to make cell therapies faster, more accessible, and potentially safer. Azalea's dual-vector system combines the cell-targeting EDVs with adeno-associated viruses (AAVs) to program the insertion of chimeric antigen receptor (CAR) genes at a specific location within the T cell genome. This method allows the engineered cell's expression to be controlled by its own natural promoters, which may lead to greater durability and efficacy.

The company launched in November 2025 with $82 million in combined seed and Series A financing. The funding was led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, and Sozo Ventures. Azalea was co-founded by 2020 Nobel laureate Jennifer Doudna, PhD; Jenny Hamilton, PhD, who serves as President and CEO; Michael Fischbach, PhD; and Justin Eyquem, PhD. The company originated from collaborative research in the labs of Dr. Doudna at UC Berkeley's Innovative Genomics Institute and Dr. Eyquem at UC San Francisco. Dr. Hamilton's work on the EDV technology began in 2018 in Dr. Doudna's lab, with the company beginning to form in 2023.

Azalea's business model is focused on developing and bringing its proprietary therapies to market. The initial capital is being used to advance its lead program, a CD19-based in vivo CAR-T therapy for B cell malignancies and autoimmune diseases, through IND-enabling studies and into clinical trials. The company is also developing a BCMA-targeted program for multiple myeloma and exploring applications for solid tumors and other cell types. By aiming to create therapeutic cells with a single injection, Azalea seeks to transform the cell and gene therapy field.

Source: Dealroom company data

At a glance

Status
Operational
Employees
28
Open positions
None listed
Dealroom signal
60.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Oncology, Genetics and genomics, Autoimmune, Crispr, Gene Therapy, Spinout, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Nov 2025 $65M $260M Sozo Ventures · RA Capital Management · Yosemite · Third Rock Ventures ↗
SPINOUTOther financing Jan 2023 $0 — University of California, San Francisco · University of California, Berkeley —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Azalea Therapeutics website traffic

Latest recorded traffic for Azalea Therapeutics is 3.6K monthly website visits, down 20% over the last three months.

Latest monthly visits3.6K 3-month web change-20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Azalea Therapeutics in the Berkeley ecosystem

Live from Dealroom

The Azalea Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Other known investors2 additional known investors

  • University of California, Berkeley
  • University of California, San Francisco
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Azalea Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.